Scribd Logo
Загрузить

Добро пожаловать в Scribd!

  • 2010-11 Seminar-Mark Ahn 10-22-10

    Загружено:

    Nien-Chi Liu
    10 просмотров1 страница
    This document announces a technology management seminar given by Dr. Mark Ahn on disruptive biotechnology innovations. Dr. Ahn will discuss the great promise but also challenges faced by emerging biotech companies in establishing legitimacy and understanding from stakeholders. While the biotech industry has created important medical advances and new companies, nascent firms must learn new roles and build necessary relationships in an environment that may not fully appreciate them. Dr. Ahn will explore opportunities and how Oregon life sciences companies can enhance their readiness to achieve scientific acceptance, access resources, and find commercial success.

    Исходное описание:

    Оригинальное название

    2010-11 Seminar-Mark Ahn 10-22-10

    Авторское право

    © Attribution Non-Commercial (BY-NC)

    Доступные форматы

    PDF, TXT или читайте онлайн в Scribd

    Этот документ был вам полезен?

    Это неприемлемый материал?

    Пожаловаться на этот документ
    This document announces a technology management seminar given by Dr. Mark Ahn on disruptive biotechnology innovations. Dr. Ahn will discuss the great promise but also challenges faced by emerging biotech companies in establishing legitimacy and understanding from stakeholders. While the biotech industry has created important medical advances and new companies, nascent firms must learn new roles and build necessary relationships in an environment that may not fully appreciate them. Dr. Ahn will explore opportunities and how Oregon life sciences companies can enhance their readiness to achieve scientific acceptance, access resources, and find commercial success.

    Авторское право:

    Attribution Non-Commercial (BY-NC)
    Скачайте в формате PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    10 просмотров1 страница

    2010-11 Seminar-Mark Ahn 10-22-10

    Загружено:

    Nien-Chi Liu
    This document announces a technology management seminar given by Dr. Mark Ahn on disruptive biotechnology innovations. Dr. Ahn will discuss the great promise but also challenges faced by emerging biotech companies in establishing legitimacy and understanding from stakeholders. While the biotech industry has created important medical advances and new companies, nascent firms must learn new roles and build necessary relationships in an environment that may not fully appreciate them. Dr. Ahn will explore opportunities and how Oregon life sciences companies can enhance their readiness to achieve scientific acceptance, access resources, and find commercial success.

    Авторское право:

    Attribution Non-Commercial (BY-NC)
    Скачайте в формате PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    из 1

    ETM

    Department of Engineering and


    Technology Management

    Technology Management Seminar Series


    Graduate Seminars – Fall 2010
    Black Swans, Blockbusters and Biotechnology:
    Reflections on the Perils and Promise of Life
    Science Innovation

    Abstract:

    Disruptive biotechnology platforms from emerging


    companies hold great promise for exploiting Day: October 22, 2010
    innovation, but often face legitimacy hurdles due to
    their liability of newness. Nascent firms must learn
    new roles with limited precedent, and establish ties Time: 3:15 pm – 4:20 pm
    Mark Ahn, PhD with an environment that may not fully understand or
    Associate Professor, Willamette University value their existence. Room: FAB 10
    1900 SW 4th Avenue
    Background: After three decades and over $90 billion in 2009
    Mark J. Ahn, is Associate Professor, Global Management at revenues, the biotechnology industry has created Portland, OR 97201
    Atkinson Graduate School of Management, Willamette important breakthroughs in human therapeutics,
    University; and Principal at Pukana Partners, Ltd. which devices and diagnostics. Also, as the market
    provides strategic consulting to life science companies. He capitalization of the biotech industry surpassing big
    previously served as Chair, Science & Technology pharma companies shows, the biotech industry is also
    Management, Victoria University at Wellington, New an important source of value and new venture
    Zealand. Dr. Ahn was also founder, President, and Chief creation with over 700 publicly listed firms in North
    Executive Officer of Hana Biosciences. Prior to Hana, he America, the European Union, and Asia-Pacific.
    served as Vice President, Hematology and corporate officer
    at Genentech, Inc., as well as held positions of increasing Are we ready for the challenges ahead? This
    responsibility at Amgen and Bristol-Myers Squibb Company. discussion will explore the hype, hope, and
    Dr. Ahn also serves on public and venture capital-backed opportunities ahead in the context of innovation,
    Board of Directors for RXi Pharmaceuticals, Access performance and value creation. Reviewing global
    Pharmaceuticals, Genesis Biopharma, Periocyte, and and local examples, we will consider how Oregon-
    Mesynthes. based life sciences firms can enhance their venture
    Ahn has published widely in the biotechnology industry readiness to achieve legitimacy in the scientific
    including recently released Building the Case for community, mobilize resources and talent, and attain
    Biotechnology commercial success.
    (http://www.buildingbiotechnology.com/casebook/).

    Вам также может понравиться